Unleashing the Potential of Ibrutinib-Loaded Nanoparticles for Cancer Treatment—A Comprehensive Review

This review provides a comprehensive examination of ibrutinib (Ibr), highlighting its wide-ranging utilization in the treatment of diverse malignancies and its potential as a viable target for solid tumor therapy on account of its ability to inhibit numerous kinases, such as Bruton’s tyrosine kinase (BTK), which is an essential component of the B-cell receptor signaling pathway and the microenvironment of cancer. The attention is directed toward the most recent developments in nanotechnology and its growing impact on the transformation of cancer therapeutics. The article examines the potential of nanotechnology in advancing approaches to enhance the efficacy of cancer treatments, overcome drug resistance, and enable the development of novel immunotherapies. An in-depth investigation into novel approaches, including nanoencapsulation and nanocarrier-mediated delivery, reveals their potential contributions to improving the therapeutic results of Ibr. The review is situated within a multidisciplinary framework. It highlights the potential uses of these emerging nanotechnological approaches to address obstacles, minimize adverse effects, and counteract potential resistance associated with Ibr treatment. This highlights nanotechnology’s profound potential in precision oncology, particularly in enhancing the therapeutic environment for hematologic cancers.